Search for any words: Search

  Chen, Ronald                    

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)   

Aggarwal, Rahul ,  Eggener, Scott ,  Chen, Ronald ,  Heller, Glenn ... -  ASCO   -  J Clin Oncol   -  2018    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  AFT-19

Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Apolo, Andrea ,  Rosenberg, Jonathan ,  Morris, Michael ... -  ASCO GU   -  J Clin Oncol   -  2019    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  A031501

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)      

Chen, Ronald C. ,  Choueiri, Toni K. ,  Feuilly, Marion ,  Meng, Jie ... -    -  Cancer   -  2020    

Manuscript -  Secondary-not-in-original -  Primary -  GU -  A031203

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)   

Zhang, Tian ,  Ballman, Karla ,  Choudhury, Atish ,  Chen, Ronald C. ... -  ASCO   -  J Clin Oncol   -  2020    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)   

Zhang, Tian ,  Ballman, Karla ,  Choudhury, Atish ,  Chen, Ronald C. ... -  IKCS   -  J Clin Oncol   -  2020    

Abstract -  Primary -  Primary -  GU -  A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian ,  Ballman, Karla ,  Choudhury, Atish ,  Chen, Ronald C. ... -  ASCO   -  J Clin Oncol   -  2019    

Abstract -  No-Endpoint -  Trial-Description-Only -  GU -  A031704